Alps Advisors Inc Enanta Pharmaceuticals Inc Transaction History

Alps Advisors Inc

  • $14.8 Billion
  • Q3 2024

A detailed history of Alps Advisors Inc transactions in Enanta Pharmaceuticals Inc stock. As of the latest transaction made, Alps Advisors Inc holds 16,038 shares of ENTA stock, worth $81,954. This represents 0.0% of its overall portfolio holdings.

Number of Shares
16,038
Previous 16,522 2.93%
Holding current value
$81,954
Previous $214,000 22.43%
% of portfolio
0.0%
Previous 0.0%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024
SELL
$10.05 - $16.54 $4,864 - $8,005
-484 Reduced 2.93%
16,038 $166,000
Q2 2024

Aug 13, 2024
BUY
$11.43 - $17.02 $18,310 - $27,266
1,602 Added 10.74%
16,522 $214,000
Q1 2024

May 14, 2024
BUY
$10.08 - $17.46 $3,215 - $5,569
319 Added 2.18%
14,920 $260,000
Q4 2023

Feb 14, 2024
SELL
$8.18 - $10.78 $7,329 - $9,658
-896 Reduced 5.78%
14,601 $137,000
Q3 2023

Nov 14, 2023
BUY
$11.09 - $22.13 $232 - $464
21 Added 0.14%
15,497 $173,000
Q2 2023

Aug 14, 2023
BUY
$20.68 - $39.85 $35,507 - $68,422
1,717 Added 12.48%
15,476 $331,000
Q1 2023

May 10, 2023
SELL
$38.82 - $54.59 $12,422 - $17,468
-320 Reduced 2.27%
13,759 $556,000
Q4 2022

Feb 14, 2023
BUY
$40.77 - $53.73 $113,911 - $150,121
2,794 Added 24.76%
14,079 $654,000
Q3 2022

Nov 14, 2022
SELL
$48.29 - $71.27 $48,386 - $71,412
-1,002 Reduced 8.15%
11,285 $585,000
Q2 2022

Aug 11, 2022
SELL
$38.13 - $76.93 $336,154 - $678,214
-8,816 Reduced 41.78%
12,287 $581,000
Q1 2022

May 16, 2022
SELL
$56.06 - $74.11 $135,553 - $179,197
-2,418 Reduced 10.28%
21,103 $1.5 Million
Q4 2021

Feb 09, 2022
SELL
$60.19 - $97.37 $75,237 - $121,712
-1,250 Reduced 5.05%
23,521 $1.76 Million
Q3 2021

Nov 15, 2021
SELL
$41.02 - $58.65 $74,902 - $107,094
-1,826 Reduced 6.87%
24,771 $1.41 Million
Q2 2021

Aug 11, 2021
SELL
$43.76 - $53.11 $425,653 - $516,600
-9,727 Reduced 26.78%
26,597 $1.17 Million
Q1 2021

May 07, 2021
BUY
$41.69 - $54.95 $1,334 - $1,758
32 Added 0.09%
36,324 $1.79 Million
Q4 2020

Feb 03, 2021
BUY
$41.16 - $47.47 $440,288 - $507,786
10,697 Added 41.79%
36,292 $1.53 Million
Q3 2020

Nov 04, 2020
SELL
$43.36 - $53.53 $73,278 - $90,465
-1,690 Reduced 6.19%
25,595 $1.17 Million
Q2 2020

Aug 05, 2020
SELL
$46.37 - $57.58 $397,900 - $494,093
-8,581 Reduced 23.93%
27,285 $1.37 Million
Q1 2020

May 06, 2020
SELL
$40.22 - $62.0 $155,973 - $240,436
-3,878 Reduced 9.76%
35,866 $1.85 Million
Q4 2019

Feb 07, 2020
BUY
$57.95 - $66.61 $27,236 - $31,306
470 Added 1.2%
39,744 $2.46 Million
Q3 2019

Nov 04, 2019
SELL
$60.08 - $88.17 $325,152 - $477,176
-5,412 Reduced 12.11%
39,274 $2.36 Million
Q2 2019

Aug 07, 2019
SELL
$81.3 - $97.35 $502,759 - $602,012
-6,184 Reduced 12.16%
44,686 $3.77 Million
Q1 2019

May 01, 2019
BUY
$69.08 - $105.66 $71,152 - $108,829
1,030 Added 2.07%
50,870 $4.86 Million
Q4 2018

Feb 04, 2019
BUY
$65.41 - $84.65 $664,303 - $859,705
10,156 Added 25.59%
49,840 $3.53 Million
Q3 2018

Oct 25, 2018
BUY
$85.46 - $126.37 $559,677 - $827,597
6,549 Added 19.76%
39,684 $3.39 Million
Q2 2018

Aug 02, 2018
BUY
$81.85 - $120.51 $985,555 - $1.45 Million
12,041 Added 57.08%
33,135 $3.84 Million
Q2 2018

Jul 25, 2018
SELL
$81.85 - $120.51 $832,332 - $1.23 Million
-10,169 Reduced 32.53%
21,094 $1.24 Million
Q1 2018

May 01, 2018
BUY
$57.91 - $92.15 $588,886 - $937,073
10,169 Added 48.21%
31,263 $2.53 Million
Q4 2017

Feb 05, 2018
BUY
$45.65 - $59.37 $107,140 - $139,341
2,347 Added 12.52%
21,094 $1.24 Million
Q3 2017

Nov 03, 2017
BUY
$37.91 - $46.8 $710,698 - $877,359
18,747
18,747 $877,000

Others Institutions Holding ENTA

# of Institutions
109
Shares Held
21.2M
Call Options Held
4.8K
Put Options Held
4.6K
View Full List

About ENANTA PHARMACEUTICALS INC

ENTA Quotes by TradingView
  • Ticker ENTA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 20,724,900
  • Market Cap $106M
  • Description
  • Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and li...
More about ENTA
Track This Portfolio

Track Alps Advisors Inc Portfolio

Follow Alps Advisors Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Alps Advisors Inc, based on Form 13F filings with the SEC.

News

Stay updated on Alps Advisors Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email